REISAMIC and Aus-REISAMIC

A partnership to help understand irAEs globally

This is a collaboration with REISAMIC (Registre des effets indésirables sévères des anticorps monoclonaux immunomodulateurs en cancérologie), a French national registry based at Institut Gustave Roussy, the largest cancer centre in Europe. REISAMIC is also a registry dedicated to recording irAEs from immune checkpoint inhibitors and has been doing this since June 2014 and is currently the largest registry to do so.

​

To understand how rheumatic irAEs develop and what relationship they have with classical rheumatic disease will clearly require a large number of patients. This registry therefore deliberately mirrors REISAMIC area to capture a minimum common dataset, with the capacity for a combined cohort allowing for earlier analysis and stronger conclusions to be drawn.

​

The study design of Aus-REISAMIC has deliberately mirrored that of REISAMIC wherever possible, and the collaboration and mentorship of both oncological and rheumatological colleagues from REISAMIC has been crucial to the founding of Aus-REISAMIC.